Flow cytometry analysis revealed that the population of CD45+CD34+ HSPCs was significantly decreased in bone marrow biopsy samples of myeloma patients compared to the healthy controls (0.43% ± 0.04% vs. 1.84% ± 0.17%, p < 0.0001; Fig. 2A,B). This evidence concerns the gene CD34 and plasma cell myeloma.